Deepak Nagra, Katie Bechman, Mark D Russell, Zijing Yang, Maryam Adas, Sujith Subesinghe, Andrew Rutherford, Edward Alveyn, Samir Patel, Chris Wincup, Arti Mahto, Christopher Baldwin, Ioasaf Karafotias, Andrew Cope, Sam Norton, James Galloway
Vaccination against pneumococcus reduces the risk of infective events, hospitalisation, and death in individual with inflammatory arthritis, particularly in those on immunomodulating therapy who are at risk of worse outcomes from pneumococcal disease. The objective of this study was to investigate the serological protection following vaccination against pneumococcal serovars over time. Methods: This was a single centre, retrospective cohort study of individuals with rheumatoid arthritis, psoriatic arthritis, or axial spondylarthritis who had previously received the PPSV23 polysaccharide pneumococcal vaccine (Pneumovax)...
January 10, 2024: Vaccines